Orchard grows team with commercial and legal leaders

A couple of additions have been made to the executive team of Orchard Therapeutics, a privately-held clinical-stage biotech based in the UK and USA.

Orchard, which specializes in developing gene therapies for rare disorders, has named Jason Meyenburg as chief commercial officer and John Ilett as general counsel and company secretary.

Mr Meyenburg held the same role at US biopharma company Sucampo Pharmaceuticals (Nasdaq: SCMP) and the rare disease specialist that it acquired, Vtesse. He also led commercial operations at Alexion Pharmaceuticals (Nasdaq: ALXN) in the USA and Latin America in the hematology, nephrology and metabolic business units, and held commercial leadership roles expanding access to the firm's products in Europe, the Middle-East, Africa and Japan.